Comparative Pharmacology
Head-to-head clinical analysis: INDO LEMMON versus ORUDIS KT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDO LEMMON versus ORUDIS KT.
INDO-LEMMON vs ORUDIS KT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes, reducing inflammation, pain, and fever.
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Oral: 25-50 mg 2-3 times daily. Maximum daily dose: 200 mg.
50 mg orally three times daily or 75 mg orally twice daily; maximum 300 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life: 2-4 hours (increased in elderly and renal impairment, up to 12 hours).
Renal excretion of unchanged drug and metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for approximately 40%.
Renal (approximately 60-80% as metabolites, <10% unchanged); biliary/fecal (approximately 20-35%).
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)